key: cord-299018-eo73yl4v
authors: Gandini, O.; Criniti, A.; Ballesio, L.; Giglio, S.; Galardo, G.; Gianni, W.; Santoro, L.; Angeloni, A.; Lubrano, C.
title: Serum Ferritin as an independent risk factor for Acute Respiratory Distress Syndrome in COVID-19 Patients in Rome Italy
date: 2020-09-15
journal: J Infect
DOI: 10.1016/j.jinf.2020.09.006
sha: 
doc_id: 299018
cord_uid: eo73yl4v

nan

Identifying the significant parameters for early progression toward worse prognosis is fundamental for the management of COVID-19 patients.

In this Journal, Zhi Lin and colleagues (1) recently reported that Chinese patients with severe Sars-CoV2 disease showed higher levels of serum ferritin than patients with not severe one, confirming data from other authors on Chinese (2) (3) and Caucasian populations (4) (5) .

Here we aimed to establish the most suitable panel for routine prognostic serum laboratory testing in COVID-19 patients upon first admission to the Emergency Department.

We thus enrolled 141 patients (59 females and 82 males, aging 64,48±16,58 years) diagnosed as COVID-19 by means of real-time polymerase chain reaction testing and admitted to the isolation ward of Emergency Department at Policlinico Umberto I Hospital in Rome, Italy, between March 2020 and June 2020. Serum samples were collected from patients upon admission before starting any treatment and tested by Laboratory Department Of all patients included, 81 patients (57%) showed mild disease (control group) and 60 (43%) showed acute respiratory distress syndrome (ARDS) and systemic inflammation (severe group). Our data strongly confirm that increased levels of ferritin were directly related with the disease severity (Fig 2A) . Particularly, not only severe group showed 2.6 times higher ferritin levels respect to mild group, but patients who needed admission to the ICU showed 5.8 times higher ferritin compared to patients with mild COVID-19. Among all parameters considered, we also noted that the neutrophil to lymphocyte ratio (NLR) was statistically correlated with the severity of disease. (Fig 2B) . Conversely, D dimer, LDH and CRP increased only in the group of critical patients (group 3), being substantially stable in the other groups characterized by mild, moderate and severe disease ( fig. 2 , panel C, D, E) Multivariate logistic regression model adjusted for several disease-related risk factors at admission, including age, sex, NLR, DD, LDH, ferritin and CRP, demonstrated that serum ferritin resulted as an independent predictor of disease severity in COVID-19 patients (OR = 1,0048, 95% CI, 1,0029 to 1,0083, P < 0,001.). If patients were grouped according to the serum ferritin level with a cut off of 500 µg/ml derived from the HLH-2004 (7) criterion, hyperferritinemia accounted for 48,22% (68/141) of patients and the hyperferritinemia group had a higher proportion of severe cases (77,94% vs 10,30%, P <0,001) than patients without hyperferritinemia. This is the first Italian report about the prognostic value of laboratory biomarkers considering 4 groups of mild, moderate, severe and critical patients with COVID-19. We clearly demonstrated that serum levels of ferritin progressively increased with the severity of disease and correlate with poor prognosis in COVID-19 patients.

Increased ferritin levels could be indicative of a strong inflammatory reaction in COVID-19 and recent studies suggest that increased levels of circulating ferritin levels play a critical role by contributing to the development of a cytokine storm (8-9) resembling macrophage activating syndrome (10) . Timely control of the cytokine storm in its early stage through immunomodulators and cytokine antagonists, as well as the reduction of lung inflammatory cell infiltration, is the key to improving the treatment success rate and reducing the mortality rate of patients with COVID-19. In this regard, ferritin evaluation could be an early, available and easy to use screening tool to assess the disease severity at the first admission in the emergency department. This test might be of crucial importance for the timely identification of patients at higher risk of an adverse outcome.

Serum ferritin as an independent risk factor for severity in COVID-19 patients

Risk Factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease

Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a metaanalysis

Covid-19 in critically ill patients in the Seattle region -case series

Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series

Clinical management of COVID-19 -Interim Guidance

HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer

Hyperferritinemia and inflammation

Crossing the Iron Gate: Why and How Transferrin Receptors Mediate Viral Entry

COVID-19) time musings: Our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning

Legends to Figure   Fig